Corbus Pharma (CRBP) Tops Q3 EPS by 2c

Corbus Pharma (NASDAQ: CRBP) reported Q3 EPS of ($0.06), $0.02 better than the analyst estimate of ($0.08).

Expected Near-Term Milestones

• Continue to screen and enroll patients in both the Phase 2 studies in CF and in systemic sclerosis to remain on track for top-line safety and efficacy results by the end of 2016;
• Continue to collaborate with the University of Pennsylvania School of Medicine on the Phase 2 dermatomyositis study, which is expected to be completed during the first half of 2017;
• File for an EU Investigational Medicinal Products authorization for Resunab with the European Medicines Agency in the fourth quarter of 2015; and
• Conduct additional mechanism of action studies with Resunab in relevant pre-clinical models.

For earnings history and earnings-related data on Corbus Pharma (CRBP) click here.

You May Also Be Interested In

• Corbus Pharmaceuticals (CRBP) PT Lowered to $52 at Oppenheimer
• Morgan Stanley Downgrades Sands China Ltd. (1928:HK) (SCHYY) to Equalweight
• Accenture (ACN) Tops Q3 EPS by 8c, Misses on Revenue; Offers FY26 EPS Guidance